Ledipasvir (GS-5885) hydrochloride is an inhibitor of thehepatitis C virus NS5A, withEC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also aSARS-CoV3CL^proinhibitor with anIC₅₀of 1.62 μM^[3].

EC50: 34 pM (GT1a), 4 pM (GT1b)^[1]
IC50: 1.62 Μm (SARS-CoV 3CLpro)^[3]

Ledipasvir hydrochloride has GT1a and 1b EC₅₀values of 31 and 4 pM, respectively, and protein-adjusted EC₅₀values of 210 pM (GT1a) and 27 pM (GT1b) and the intrinsic EC₅₀of 39 is 310 fM for GT1a and 40 fM for GT1b. Ledipasvir hydrochloride is highly protein-bound both in human serum and in the cell-culture medium (containing 10% BSA) of the replicon assay^[1]. Ledipasvir hydrochloride exhibits an EC₅₀value of 141 nM against the JFH/3a-NS5A replicon^[2].

Ledipasvir hydrochloride is remarkable not only on the basis of its high replicon potency but also on the basis of its low clearance, good bioavailability, and long half-lives in rat, dog, and monkey and low predicted clearance in human. The pharmacokinetics of Ledipasvir hydrochloride is measured in rats and dogs. Ledipasvir shows good half-lives (rat 1.83 hr, dog 2.63 hr) in plasma, low systemic clearance (CL), and moderate volumes of distribution (Vss) that are greater than total body water volume^[1].

925.46

C₄₉H₅₅ClF₂N₈O₆

盐酸雷迪帕韦；盐酸来地帕韦

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.